We are thrilled to share that we have secured an additional €2.85M bringing our Series A round to nearly €12M

The funds build on a €30M in legacy to support the expansion of our immunomodulation program, EXL01 addressing multiple indications from cancer to inflammatory and infectious diseases.

This new financing will allow us to focus on advancing our proof-of-concept phase 2 studies and prepare for a new cancer indication in the US.

Thank you to BIOCODEX for leading the round and the belief from Crescent Capital Ventures, UI Investissement and Forepont Capital Partners in the therapeutic potential of EXL01

‍